Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optivate in Children Under 6 with Severe Haemophilia A
NCT02246894Phase 3Completed
- Sponsor
- Bio Products Laboratory
- Start
- Nov 2003
- Primary completion
- Jan 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of factor viii + von Willebrand factor in hemophilia A, sponsored by Bio Products Laboratory. Primary endpoint: Consumption of FVIII at 26 weeks. Started Nov 2003; status: completed.
02
Drugs
factor viii + von Willebrand factor
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02246894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246894.